Nvelop Therapeutics
Main focus: Developing novel delivery methods for gene-editing tools using programmable, non-viral delivery vehicles.
Company stage: Pre-clinical
Diseases: Several different diseases across multiple tissues
Genome-editing tool: CRISPR-Cas9, base editing, and prime editing
Funding stage: $100 million from investors including Newpath Partners, Atlas Venture, F-Prime Capital and 5AM Ventures (as of April 2024)
Location: Cambridge, Massachusetts, USA
Website: https://www.nveloptx.com/
Pipeline:
Partners:
Nvelop Therapeutics is a biotechnology company that focuses on improving delivery platforms for gene editing, addressing current limitations in the field. Their technology aims to enhance delivery efficiency by increasing package capacity and tissue specificity, while offering the safety advantages of non-viral particles. The company focuses on developing programmable particles that enable selective targeting to advance therapeutic development for previously undruggable diseases.